Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...
Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end report that it's in a stronger position going into 2025 thanks to improved ...
President Donald Trump’s nominee for secretary of the Department of Health and Human Services (HHS), Robert F. Kennedy Jr. | ...
Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
The Partnership to Fight Infectious Disease has put out a timely notice about support for vaccines. Forty-five minutes before ...
A squadron of senators is once again putting forward a proposal to boost price transparency in direct-to-consumer ...
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...
Want the eyeballs of people with obesity? Think TV. That is a takeaway from a CMI survey that suggests the fight for ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback